<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">Inflammatory bowel disease</z:e> (IBD) exposes patients to an increased risk of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (i-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) and differences between i-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and <z:hpo ids='HP_0003745'>sporadic</z:hpo> <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (s-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) pathogenesis were reported </plain></SENT>
<SENT sid="1" pm="."><plain>In s-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, studies indicate abnormalities in the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-suppressor gene Cdx2 </plain></SENT>
<SENT sid="2" pm="."><plain>This study compared CDX2, β-catenin, and TP53 expression in i-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, s-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, noncancer IBD, and <z:mpath ids='MPATH_458'>normal</z:mpath> control colonic mucosa </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Expression was investigated by immunohistochemistry in 10 <z:mpath ids='MPATH_458'>normal</z:mpath>, 20 s-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, 11 noncancer colonic IBD and 30 i-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> samples, and in four samples of <z:hpo ids='HP_0100280'>Crohn's disease</z:hpo> (CD)-associated small bowel <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> (i-SBA) </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: In <z:mpath ids='MPATH_458'>normal</z:mpath> and noncancer IBD samples, CDX2 was confined to the colonocytes nuclei </plain></SENT>
<SENT sid="5" pm="."><plain>CDX2 expression was <z:mpath ids='MPATH_458'>normal</z:mpath> in 90% of i-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, regardless of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> differentiation or <z:mp ids='MP_0001845'>inflammation</z:mp> intensity </plain></SENT>
<SENT sid="6" pm="."><plain>By contrast, CDX2 expression was altered in 45% s-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, particularly at the front of invasion in undifferentiated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>. β-Catenin was restricted to cell membrane in <z:hpo ids='HP_0000001'>all</z:hpo> controls, in 91% noncancer IBD, and in 84% i-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> samples, whereas 35% s-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> showed cytoplasmic redistribution and exclusive nuclear staining at the front of invasion </plain></SENT>
<SENT sid="7" pm="."><plain>TP53 was strongly and homogeneously expressed in i-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> nuclei compared to <z:mpath ids='MPATH_458'>normal</z:mpath> control or s-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, and increases with <z:mp ids='MP_0001845'>inflammation</z:mp> intensity </plain></SENT>
<SENT sid="8" pm="."><plain>Nested or diffuse TP53 was found in 81.8% of noncancer IBD samples with a higher proportion of TP53-expressing cells in the most inflamed samples </plain></SENT>
<SENT sid="9" pm="."><plain>CDX2, β-catenin, and TP53 expression in CD-associated SBA appears similar to that of i-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Neither Cdx2 nor β-catenin alterations are prominent features of i-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: In i-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and CD-associated SBA, <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> is associated early with p53 mutations and to <z:mp ids='MP_0001845'>inflammation</z:mp> intensity </plain></SENT>
</text></document>